Effects of Haloperidol, Olanzapine, Ziprasidone, and PHA-543613 on Spatial Learning and Memory in the Morris Water Maze Test in Naïve and MK-801-treated Mice

Overview

Journal Brain Behav

Specialty Psychology

Date 2017 Aug 23

PMID 28828223

Citations 13

Authors

Houxu Ning

Dong Cao

Haidong Wang

Bing Kang

Shiping Xie

Yujing Meng

Affiliations

Soon will be listed here.

Abstract

Introduction: Cognitive impairment is the core symptom of schizophrenia, significantly impacting the functional outcome. Improvement of cognitive function has been an important aspect of the treatment of schizophrenia. Therefore, this study is to demonstrate the effects of first-generation antipsychotic haloperidol, second-generation antipsychotic olanzapine and ziprasidone, and alpha-7 nicotinic acetylcholine receptor agonist PHA-543613 on spatial learning and memory.

Material And Methods: C57BL/6 mice received intraperitoneal injections of haloperidol (2 mg/kg), olanzapine (2.5 mg/kg), ziprasidone (2 mg/kg), and PHA-543613 (1 mg/kg), and cognitive dysfunctions were induced by MK-801 (0.1 mg/kg). Morris water maze was used for investigating the effects of all agents.

Results: Mk-801 significantly increased the mean escape latency to the platform and decreased the number of platform area crossings. Ziprasidone had no effect on the mean escape latency to platform and the number of platform area crossings in naïve mice, but haloperidol, olanzapine, and PHA-543613 did not. Haloperidol and olanzapine significantly increased the mean escape latency to platform and decreased the number of platform area crossings, while ziprasidone and PHA-543613 did not. All the agents had no effect on swimming speed.

Conclusions: Ziprasidone and alpha-7 nicotinic acetylcholine receptor agonist PHA-543613 might be helpful in the treatment of CIAS.

Citing Articles

Investigation of protective effects of olanzapine on impaired learning and memory using behavioral tests in a rat model of Alzheimer's disease.

Komaki S, Amiri P, Safari S, Abbasi E, Ramezani-Aliakbari F, Golipoor M Front Aging Neurosci. 2025; 17:1376074.

PMID: 40018516 PMC: 11865076. DOI: 10.3389/fnagi.2025.1376074.

Cellular Mechanisms of Cognitive Enhancement: The Modulation of the Firing Activity and the Responsiveness of Rat Hippocampal Neurons by Memantine and Alpha7 Nicotinic Acetylcholine Receptor Ligands.

Nagy L, Bali Z, Ledneczki I, Nemethy Z, Lendvai B, Hernadi I ASN Neuro. 2024; 16(1):2371160.

PMID: 39024573 PMC: 11262468. DOI: 10.1080/17590914.2024.2371160.

Drug Repurposing of Metformin for the Treatment of Haloperidol-Related Behavior Disorders and Oxidative Stress: A Preliminary Study.

Jitca G, Gall Z, Jitca C, But M, Majai E Pharmaceutics. 2024; 16(3).

PMID: 38543297 PMC: 10974093. DOI: 10.3390/pharmaceutics16030403.

MK-801 and cognitive functions: Investigating the behavioral effects of a non-competitive NMDA receptor antagonist.

Janus A, Lustyk K, Pytka K Psychopharmacology (Berl). 2023; 240(12):2435-2457.

PMID: 37725119 PMC: 10640442. DOI: 10.1007/s00213-023-06454-z.

The Effects of Four Compounds That Act on the Dopaminergic and Serotonergic Systems on Working Memory in Animal Studies; A Literature Review.

Grosu S, Chirila M, Rad F, Enache A, Handra C, Ghita I Brain Sci. 2023; 13(4).

PMID: 37190512 PMC: 10136467. DOI: 10.3390/brainsci13040546.

References

Abdul-Monim Z, Reynolds G, Neill J . The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat. J Psychopharmacol. 2003; 17(1):57-65. DOI: 10.1177/0269881103017001700. View

Minzenberg M, Carter C . Developing treatments for impaired cognition in schizophrenia. Trends Cogn Sci. 2011; 16(1):35-42. DOI: 10.1016/j.tics.2011.11.017. View

Barch D . The cognitive neuroscience of schizophrenia. Annu Rev Clin Psychol. 2007; 1:321-53. DOI: 10.1146/annurev.clinpsy.1.102803.143959. View

Young J, Geyer M . Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia. Biochem Pharmacol. 2013; 86(8):1122-32. PMC: 3797190. DOI: 10.1016/j.bcp.2013.06.031. View

Yamazaki M, Harada K, Yamamoto N, Yarimizu J, Okabe M, Shimada T . ASP5736, a novel 5-HT5A receptor antagonist, ameliorates positive symptoms and cognitive impairment in animal models of schizophrenia. Eur Neuropsychopharmacol. 2014; 24(10):1698-708. DOI: 10.1016/j.euroneuro.2014.07.009. View

Arnt J, Skarsfeldt T . Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology. 1998; 18(2):63-101. DOI: 10.1016/S0893-133X(97)00112-7. View

Javitt D . Glutamatergic theories of schizophrenia. Isr J Psychiatry Relat Sci. 2010; 47(1):4-16. View

Gaspar P, Bustamante M, Silva H, Aboitiz F . Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications. J Neurochem. 2009; 111(4):891-900. DOI: 10.1111/j.1471-4159.2009.06325.x. View

Nikiforuk A, Kos T, Potasiewicz A, Popik P . Positive allosteric modulation of alpha 7 nicotinic acetylcholine receptors enhances recognition memory and cognitive flexibility in rats. Eur Neuropsychopharmacol. 2015; 25(8):1300-13. DOI: 10.1016/j.euroneuro.2015.04.018. View

10.

Sadigh-Eteghad S, Talebi M, Mahmoudi J, Babri S, Shanehbandi D . Selective activation of α7 nicotinic acetylcholine receptor by PHA-543613 improves Aβ25-35-mediated cognitive deficits in mice. Neuroscience. 2015; 298:81-93. DOI: 10.1016/j.neuroscience.2015.04.017. View

11.

Anderson V, Mcilwain M, Kydd R, Russell B . Does cognitive impairment in treatment-resistant and ultra-treatment-resistant schizophrenia differ from that in treatment responders?. Psychiatry Res. 2015; 230(3):811-8. DOI: 10.1016/j.psychres.2015.10.036. View

12.

Singh S, Kaur H, Sandhir R . Fractal dimensions: A new paradigm to assess spatial memory and learning using Morris water maze. Behav Brain Res. 2015; 299:141-6. DOI: 10.1016/j.bbr.2015.11.023. View

13.

Volavka J, Czobor P, Sheitman B, Lindenmayer J, Citrome L, McEvoy J . Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry. 2002; 159(2):255-62. DOI: 10.1176/appi.ajp.159.2.255. View

14.

Zemanova A, Stankova A, Lobellova V, Svoboda J, Vales K, Vlcek K . Visuospatial working memory is impaired in an animal model of schizophrenia induced by acute MK-801: an effect of pretraining. Pharmacol Biochem Behav. 2013; 106:117-23. DOI: 10.1016/j.pbb.2013.03.014. View

15.

Brown J, Rueter L, Zhang M . Predictive validity of a MK-801-induced cognitive impairment model in mice: implications on the potential limitations and challenges of modeling cognitive impairment associated with schizophrenia preclinically. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 49:53-62. DOI: 10.1016/j.pnpbp.2013.11.008. View

16.

Wang Q, Wang F, Li X, Yang Q, Li X, Xu N . Electroacupuncture pretreatment attenuates cerebral ischemic injury through α7 nicotinic acetylcholine receptor-mediated inhibition of high-mobility group box 1 release in rats. J Neuroinflammation. 2012; 9:24. PMC: 3297509. DOI: 10.1186/1742-2094-9-24. View

17.

Bymaster F, Calligaro D, Falcone J, Marsh R, Moore N, Tye N . Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996; 14(2):87-96. DOI: 10.1016/0893-133X(94)00129-N. View

18.

Vorhees C, Williams M . Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc. 2007; 1(2):848-58. PMC: 2895266. DOI: 10.1038/nprot.2006.116. View

19.

Millan M . Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors. J Pharmacol Exp Ther. 2000; 295(3):853-61. View

20.

Karamihalev S, Prickaerts J, van Goethem N . Donepezil and the alpha-7 agonist PHA 568487, but not risperidone, ameliorate spatial memory deficits in a subchronic MK-801 mouse model of cognitive impairment in schizophrenia. Behav Brain Res. 2014; 272:248-51. DOI: 10.1016/j.bbr.2014.07.017. View